US2010068257A1PendingUtilityA1

Sustained Release of Antiinfectives

70
Assignee: TRANSAVE INCPriority: Oct 29, 2002Filed: Apr 15, 2009Published: Mar 18, 2010
Est. expiryOct 29, 2022(expired)· nominal 20-yr term from priority
A61P 31/00A61K 9/0078Y10S977/906A61K 31/7036A61K 31/496A61K 31/545A61K 31/407A61K 9/127Y10S977/773Y10S977/907A61K 9/0073A61K 9/48Y02A50/30
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.

Claims

exact text as granted — not AI-modified
1 . A method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both. 
     
     
         2 . The method of treating or ameliorating of  claim 1 , wherein the antiinfective is an aminoglycoside, a tetracycline, a sulfonamide, para-aminobenzoic acid, a diaminopyrimidine, a quinolone, a beta-lactam, a beta-lactam and a beta-lactamase inhibitor, chloramphenicol, a macrolide, lincomycin, clindamycin, spectinomycin, polymyxin B, colistin, vancomycin, bacitracin, isoniazid, rifampin, ethambutol, ethionamide, aminosalicylic acid, cycloserine, capreomycin, a sulfone, clofazimine, thalidomide, or combination thereof. 
     
     
         3 . The method of treating or ameliorating of  claim 1 , wherein the antiinfective is a polyene antifungal, flucytosine, imidazole, triazole, griseofulvin, terconazole, butoconazole ciclopirax, ciclopirox olamine, haloprogin, tolnaftate, naftifine, terbinafine, or combination thereof. 
     
     
         4 . The method of treating or ameliorating of  claim 1 , wherein the antiinfective is an aminoglycoside. 
     
     
         5 . The method of treating or ameliorating of  claim 4 , wherein the administrated amount is 100 mg or less for every day of treatment or amelioration. 
     
     
         6 . The method of treating or ameliorating of  claim 5 , wherein the dosing is once a day or less. 
     
     
         7 . The method of treating or ameliorating of  claim 5 , wherein the dosing is once every two days or less. 
     
     
         8 . The method of treating or ameliorating of  claim 5 , wherein the dosing is once every three days or less. 
     
     
         9 . The method of treating or ameliorating of  claim 1 , wherein the antiinfective is amikacin. 
     
     
         10 . The method of treating or ameliorating of  claim 9 , wherein the administrated amount is 100 mg or less for every day of treatment or amelioration. 
     
     
         11 . The method of treating or ameliorating of  claim 10 , wherein the dosing is once a day or less. 
     
     
         12 . The method of treating or ameliorating of  claim 10 , wherein the dosing is once every two days or less. 
     
     
         13 . The method of treating or ameliorating of  claim 10 , wherein the dosing is once every three days or less. 
     
     
         14 . The method of treating or ameliorating of  claim 1 , wherein the infection to be treated or ameliorated is a  pseudomonas  (e.g.,  P. aeruginosa, P. paucimobilis, P. putida, P. fluorescens,  and  P. acidovorans ), staphylococcal, Methicillin-resistant  Staphylococcus aureus  (MRSA), streptococcal (including by  Streptococcus pneumoniae ),  Escherichia coli, Klebsiella, Enterobacter, Serratia, Haemophilus, Yersinia pestis, Burkholderia pseudomallei, B. cepacia, B. gladioli, B. multivorans, B. vietnamiensis, Mycobacterium tuberculosis, M. avium  complex (MAC) ( M. avium  and  M. intracellulare ),  M. kansasii, M. xenopi, M. marinum, M. ulcerans,  or  M. fortuitum  complex ( M. fortuitum  and  M. chelonei ) infection. 
     
     
         15 . The method of treating or ameliorating of  claim 1 , wherein the infection to be treated or ameliorated is a  pseudomonas  infection. 
     
     
         16 . The method of treating or ameliorating of  claim 1 , wherein the infection to be treated or ameliorated is a  P. aeruginosa  infection. 
     
     
         17 . The method of treating or ameliorating of  claim 1 , wherein the administrated amount is 50% or less of the comparative free drug amount 
     
     
         18 . The method of treating or ameliorating of  claim 17 , wherein the dosing is once a day or less. 
     
     
         19 . The method of treating or ameliorating of  claim 17 , wherein the dosing is once every two days or less. 
     
     
         20 . The method of treating or ameliorating of  claim 17 , wherein the dosing is once every three days or less. 
     
     
         21 . The method of treating or ameliorating of  claim 1 , wherein the administrated amount is 35% or less of the comparative free drug amount. 
     
     
         22 . The method of treating or ameliorating of  claim 1 , wherein the administrated amount is 20% or less of the comparative free drug amount. 
     
     
         23 . The method of treating or ameliorating of  claim 1 , wherein the administrated amount is 10% or less of the comparative free drug amount. 
     
     
         24 . The method of treating or ameliorating of  claim 1 , wherein the effective amount is one effective to treat or ameliorate after symptoms of lung infection have arisen 
     
     
         25 . A method of treating or ameliorating pulmonary infection in an animal comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, and (ii) the dosing is once every two days or less.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.